Article Details

Seelos eyes chronic ketamine dosing after bagging rights to sublingual candidate | FiercePharma

Retrieved on: 2021-11-30 17:24:18

Tags for this article:

Click the tags to see associated articles and topics

Seelos eyes chronic ketamine dosing after bagging rights to sublingual candidate | FiercePharma. View article details on hiswai:

Excerpt

Seelos Therapeutics has secured near-global rights to a sublingual ketamine wafer, agreeing to pay iX Biopharma $9 million upfront to take control ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up